The company reported Q2 2026 hospital revenue of $6.7 million and plans a manufacturing transfer in H1 2027.
BioStem Technologies raised its full-year 2026 revenue outlook to a range of $26M-$29M, citing stronger hospital sales. The company reported $6.7 million in hospital revenue for Q2 2026, its first full quarter as a predominantly hospital-focused business.
Management noted sequential growth in hospital revenue and highlighted progress toward a manufacturing transfer planned for the first half of 2027. The revised forecast follows a period of operational adjustments as BioStem shifts its business model.
No immediate market reaction was disclosed in the earnings call summary.